fainting or feeling dizzy
A large cardiovascular outcome trial in high-risk T2D patients treated with the GLP-1 analog liraglutide (LEADER) demonstrated impressive reductions in CV mortality (22%
More on, ADA and AACE Guidelines prefer GLP1RA over DPP4i for patients with established ASCVD or indicators of high ASCVD risk, CKD 3, or heart failure 1
Applying those same ingredients to the skin introduces an absorption barrier that has not been validated for this purpose (7,9,10), and no New Zealand regulator has approved any over-the-counter GLP-1 patch for safety or efficacy
Schedule a consult with me, Carly Neubert BA, NC
Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of dulaglutide is to stimulate functioning islet cells to produce more insulin